Lantern Pharma Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc.(Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Common Stock Name of each exchange on which registeredThe Nasdaq Stock Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filerEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 10, 2026 the registrant had 12,784,146 shares of common stock, $0.0001 par value per share outstanding. Table of Contents PART I – FINANCIAL INFORMATION Item 1.Financial Statements.1Condensed Consolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 20251Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2026 and 2025(unaudited)2Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2026and 2025 (unaudited)3Condensed Consolidated Statements of Changes in Stockholders’ (Deficit) Equity for the three and six monthsended June 30, 2026 and 2025 (unaudited)4Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025(unaudited)5Notes to Condensed Consolidated Financial Statements (unaudited)6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.20Item 3.Quantitative and Qualitative Disclosures About Market Risk.29Item 4.Controls and Procedures.30 PART II – OTHER INFORMATION Item 1A.Risk Factors.31Item 6.Exhibits.31Signatures32 FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Wemake such forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act,Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements, other thanstatements of historical fact, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, futurepreclinical study activities, future clinical trial activities, future research activities, future financial position, projected costs, prospects,plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “could,”“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “model”, “objective”, “aim,”“upcoming”, “should,” ‘will” “would,” or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements reflect our currentviews with respect to future events and are based on assumptions and subject to risks and uncertainties. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements relating to: ●the existence of substantial doubt regarding our ability to continue as a going concern in the absence of obtainingsubstantial additional funding;●our ability to secure sufficient funding and alternative sources of funding to support our existing and proposed preclinicalstudies and clinical trials;●the potential advantages of our RADR®platform in identifying drug candidates and patient populations that are likely torespond to a drug candidate;●our strategic plans to advance the development of any of